Find Academic Supervisors

Haiyan ZhouView profile

Professor

• Genetic Medicine
• Nucleic Acid Therapeutics
• Rare Diseases
• +7 more

Professor Haiyan Zhou serves as Professor of Genetic Medicine at University College London (UCL), affiliated with the Institute of Child Health and Department of Genetics and Genomic Medicine. She directs the UK Platform of Nucleic Acid Therapy (UPNAT Node) for rare diseases, co-leads the Therapeutic Innovation and Trials Community Domain in Genomics England, and acts as Deputy Theme Lead for Novel Therapies at the NIHR Great Ormond Street Hospital Biomedical Research Centre. Prof. Zhou earned her MD-PhD in clinical medicine and skin pharmacology from Peking Union Medical College. Her research pioneers nucleic acid therapeutics (NAT) for rare genetic disorders, focusing on RNA-based approaches including antisense oligonucleotides, siRNA, and RNA editing for neuromuscular diseases. The Zhou Lab collaborates extensively across UCL with experts in muscular dystrophies, respiratory disorders, neurological conditions, and metabolic diseases to translate experimental therapies into clinical applications for pediatric patients. Recent publications (2023-2025) reveal a dominant focus on optimizing RNA therapeutics for spinal muscular atrophy and collagen VI-related dystrophies, with key advances in allele-specific silencing, biomarker discovery, and preclinical-to-clinical translation. Her work consistently bridges molecular mechanisms with therapeutic development, emphasizing tissue-specific delivery and treatment response monitoring. Scientific recognition includes: Harrington UK Rare Disease Scholar (2021) Lea Rose Spinal Muscular Atrophy Award (2017, 2015) Young scientist award from The SMA trust (2011) President Prize for the Young Myologist of the Year (World Muscle Society, 2006) As principal investigator, Prof. Zhou secures funding from MRC, NIHR, and the Harrington Discovery Institute for RNA therapeutic development. She mentors early-career researchers through e-COST Action, Marie Skłodowska-Curie ITN, and UCL programs while supervising MSc/PhD students. Her leadership extends to directing UCL's MSc Personalized Medicine and Novel Therapies Programme and serving on multiple education committees. The Zhou Lab operates as a multidisciplinary hub within UCL's Institute of Child Health, collaborating closely with the Dubowitz Neuromuscular Centre and international consortia like the Oligonucleotide Therapeutic Society. Current initiatives focus on individualized RNA therapy for pediatric rare diseases, with active pipelines for hereditary sensory neuropathy and COL6-related dystrophies.

• Biomedical Engineering
• Nanotechnology
• Tumor Therapy
• +4 more

Liu Hongmei is a Researcher and Master's Supervisor at Southern University of Science and Technology's Department of Biomedical Engineering. Holding a Ph.D. from the Chinese Academy of Sciences, she specializes in micro-nano robotics and tissue engineering for tumor therapy, with over 66 publications and 12 patents. Her work bridges biomedical engineering and nanotechnology for precision cancer treatments. B.S., Biological Sciences, Harbin Normal University (2005) M.S., Botany, Northeast Agricultural University (2008) Ph.D., Biochemical Engineering, Chinese Academy of Sciences (2015) Her research focuses on biomaterials engineering , nanoparticle drug delivery , and microenvironment-responsive hydrogels . Key areas include glioma therapy, traumatic brain injury recovery, and intervertebral disc degeneration treatments. Recent work explores pH/ROS/inflammation-triggered hydrogels and bioengineered bacteria for disease modulation. Article trends show a strong emphasis on nanoparticle design (2014-2025) for glioma, hydrogel development (2017-2025) for tissue repair, and biomimetic material synthesis (2023-2025) inspired by spider silk and meniscus structures. Sub-fields span pyroptosis inhibition, epigenetic reprogramming, and microbiome engineering. Jiangsu Science and Technology Award (2020) Jiangsu Medical Science and Technology Award (2020) Jiangsu Educational Science Research Award (2021) Chinese Medical Doctor Association's Outstanding Young Scientist (2018) Liu has supervised numerous projects including National Natural Science Foundation of China grants, Jiangsu Province Key R&D Program funding, and Shenzhen City General Projects. She holds 12 Chinese invention patents and collaborates with institutions like the UNESCO Centre for Higher Education Innovation.

Zahoor ShahView profile

Professor

• Neuroprotection
• Stroke Research
• Cerebrovascular Diseases
• +3 more

Zahoor Shah, Ph.D. , is a Professor and Vice Chair in the Department of Medicinal and Biological Chemistry at the College of Pharmacy and Pharmaceutical Sciences , The University of Toledo . He serves as Associate Dean for Graduate Education and Research and Program Director . Dr. Shah obtained his doctorate in Toxicology from Hamdard University (New Delhi, India) and completed postdoctoral training at the University of Louisville (2005) and Johns Hopkins University (2007). 2005: Postdoctoral Fellow, University of Louisville 2007: Postdoctoral Fellow, Johns Hopkins University 2009: Instructor, Johns Hopkins University Dr. Shah’s research focuses on identifying molecular targets and developing drugs for ischemic and hemorrhagic brain injuries . Key areas include: Neuroprotective agents targeting oxidative stress and inflammation Role of Nrf2/HO1 pathway in stroke recovery Mechanistic studies of cofilin signaling in neuroinflammation Preclinical models of stroke (t-MCAO, pMCAO, BCCAO) and zebrafish Alzheimer’s models Development of ROS-sensitive nitric oxide synthase inhibitors Patents in oxidative stress-related therapies His 15 most recent articles (2022–2024) emphasize: Therapeutic targeting of cofilin and neuroinflammation in stroke and neurodegenerative diseases Interplay between gut microbiota and cognitive decline Preclinical validation of anti-inflammatory agents (e.g., triazole-pyrimidine hybrids) Impact of metabolic factors (diabetes, hyperglycemia) on brain injury outcomes Dr. Shah has received major grants including NINDS R01 (2020–2025) and NIA R01 (2018–2023), and holds patents for neuroprotective compositions (US Patent 10,590,119; provisional applications D2018-11 and D2019-35). He has published over 83 peer-reviewed articles and mentored numerous graduate and undergraduate students.

Denina SimmonsView profile

Associate Professor

• Aquatic Toxicology
• Bioinformatics
• Proteomics
• +3 more

Denina Simmons is an Associate Professor and Canada Research Chair (Tier II) at Ontario Tech University's Faculty of Science, affiliated with the Applied Biosciences (Graduate) and Biology (Undergraduate) departments. Her research focuses on Aquatic Toxicology , particularly using proteomics and metabolomics to non-lethally monitor aquatic wildlife health. She holds a PhD in Environmental and Life Sciences from Trent University (2009), an MSc in Watershed Ecosystems (Trent University, 2005), and a BSc in Applied Chemical and Biological Sciences (Ryerson University, 2000). Her work bridges bioinformatics and ecotoxicology , addressing human impacts on aquatic ecosystems through omics technologies. Recent projects include studying pharmaceutical bioaccumulation in fish, pesticide effects on bats, and lithium's physiological disruption in trout. She has delivered over 20 invited lectures since 2013, including at the University of Toronto and Environment Canada. Key awards include NSERC Post-doctoral and Doctoral Fellowships. Her research has produced over 30 peer-reviewed articles, emphasizing interdisciplinary approaches to environmental health challenges. She teaches BIOL 4020: Introduction to Environmental Toxicology and BIOL 4030: Advanced Topics in Environmental Toxicology .

Andrew CareView profile

Senior Lecturer

• Nanomedicine
• Synthetic Biology
• Drug Delivery Systems
• +3 more

Andrew Care is a Senior Lecturer and Academic Director of the Biologics Innovation Facility (BIF) at the University of Technology Sydney (UTS), within the School of Life Sciences. He holds a PhD in Chemistry and Biomolecular Sciences from Macquarie University and has held prestigious fellowships, including the Cancer Institute NSW Early Career Fellowship and UTS Chancellor's Research Fellowship. His research focuses on combining synthetic biology and nanomedicine to engineer biologically-derived nanoparticles for drug delivery and vaccines. He is actively involved in industry collaborations, notably as a Chief Investigator in the ARC ITRC IDEAL Hub. Teaching and leadership roles include Program Director for the Biomedical Engineering program and coordination of the Australasian Synthetic Biology Challenge, which fosters student innovation. He has been recognized with a UTS Vice-Chancellor’s Teaching Citation and multiple Dean’s Awards for integrating Work Integrated Learning (WIL) and enhancing student engagement. His contributions to education and research excellence have earned awards for collaboration and partnership. Research interests span nanoparticle engineering, neurodegenerative disease therapies, and biomanufacturing. Notable projects include developing an Alzheimer’s vaccine using encapsulin protein cages and investigating nanoparticle interactions in brain cells. His work bridges academia and industry, emphasizing translational applications in healthcare. Awards: UTS Vice-Chancellor’s Research Excellence Award (2024), UTS Teaching Citation (2024), Multiple Dean’s Awards for Science Initiative, Innovation, and Student Experience. Leadership: Academic Lead of BIF, Editor of SYNTHESIS Magazine, and EMCR Representative in research committees. Grants: Providence Foundation Project Grant (2023), ARC IDEAL Hub funding. Andrew’s labs, including the Biologics Innovation Facility, provide advanced training in biomanufacturing and nanomedicine, equipping students and professionals for industry roles. His research aims to address unmet clinical needs through innovative biomedical solutions.

Barbara WollenbergView profile

Professor

• Immunology
• Oncology
• Cancer Biology
• +3 more

Prof. Barbara Wollenberg is a Professor of Otorhinolaryngology at the Technical University of Munich (TUM), leading the Chair of Otorhinolaryngology within the TUM School of Medicine and Health. She specializes in translational research on immunological interactions in head and neck cancer, focusing on biomarker discovery and tumor immune evasion mechanisms. Her work integrates molecular approaches with clinical trials, particularly in immunotherapy. She holds a medical degree from Saarland University and Ludwig-Maximilians-University Munich (LMU), with a doctorate in Immunology and habilitation from LMU. She completed residencies in ENT and additional qualifications in allergology and skull base surgery. Notably, she received a Heisenberg Fellowship from DFG (2001) and joined TUM in 2019 after a tenure at the University of Lübeck. Her research emphasizes biomarkers, tumor-immune dynamics, and immunotherapies for head and neck cancers. Key awards include the Acta Prize (2019), Georg Heberer Prize (2004), and Monika Kutzner Prize (2001). Her publications span immunology, oncology, and translational medicine, with recent work exploring PD-1 inhibitors, tumor microenvironments, and novel therapeutic strategies.

Dinshaw PatelView profile

Professor

• Structural Biology
• Biochemistry
• CRISPR-Cas Systems
• +7 more

Dinshaw Patel is a Professor at the Structural Biology Program of Memorial Sloan Kettering Cancer Center (MSKCC), holding the Abby Rockefeller Mauzé Chair in Experimental Therapeutics. He has affiliations with Columbia University, The Rockefeller University, and Weill Cornell Medicine through collaborative research projects. PhD in Photochemistry, New York University Postdoctoral training in Biochemistry and Biophysics 17 years at AT&T Bell Laboratories Professor at Columbia University-Health Sciences His research focuses on structural biology of macromolecular recognition systems, particularly CRISPR-Cas surveillance complexes, cGAS-STING pathways, Structure Maintenance of Chromosomes (Smc5/6, MRX) complexes, and epigenetic regulation via histone/DNA modifications. His work spans RNA-mediated processes (siRNA/piRNA pathways), molecular chaperones, and riboswitches/ribozymes. Recent projects include structural characterization of bacterial antiphage defense systems (Lamassu, Kiwa), small molecule inhibitors targeting SARS-CoV-2 RNA capping machinery, and complexes involved in leukemias/lymphomas. Publications highlight structural elucidation of CRISPR-Cas systems using cryo-EM and x-ray crystallography, DNA repair mechanisms, and RNA-protein interaction dynamics. Key collaborations include Luciano Marraffini (Rockefeller), Xiaolan Zhao (MSKCC), and Thomas Tuschl (Rockefeller). National Academy of Sciences member AAAS member AT&T Bell Labs Distinguished Technical Staff Award New York University Distinguished Alumnus Award FEZANA Excellence in Profession Award Lifetime Achievement, American Association of Indian Scientists in Cancer Research Students and trainees benefit from his expertise in structural biology techniques (NMR, crystallography, cryo-EM), biochemical assays, and biophysical approaches. His lab participates in the Tri-Institutional PhD Program in Chemical Biology and maintains affiliations with multiple institutions including Beijing Advanced Innovation Center for Structural Biology and ETH Zürich.

Guizhi ZhuView profile

Associate Professor

• Immunology
• Nucleic Acid Engineering
• Functional Biomaterials
• +10 more

Guizhi Zhu (Julian) is an Associate Professor in the Department of Pharmaceutical Sciences at the University of Michigan — Ann Arbor . He is also a Center Member at the Rogel Cancer Center and Biointerfaces Institute . His research focuses on RNA-based therapeutics and vaccines at the intersection of immunology, nucleic acid engineering, and functional biomaterials. Dr. Zhu earned a B.S. from Nankai University (China), a Ph.D. from the University of Florida (USA), and completed postdoctoral training at the National Institutes of Health . His work has been continuously supported by federal grants from NIH , DoD , and ACS , including a $2.3M NIH/NCI R01 grant (2022-2027) and a DoD Breast Cancer Research Breakthrough Award (2022-2025). Developing circRNA and mRNA vaccines for cancer and infectious diseases Designing nucleic acid immunotherapeutics (circRNA, gene-editing gRNA, siRNA) Engineering cGAS-STING-targeted immunomodulators for cancer and autoimmune diseases Creating biomaterials delivery systems : lipid nanoparticles, polymeric microneedles, hydrogels His 15 most recent publications (2020-2025) demonstrate expertise in circular RNA vaccines , nucleic acid delivery , and combination immunotherapy . His 2022 review in Journal of Controlled Release has been cited 231 times, highlighting his leadership in RNA therapeutics. 2022 : Mary Ann Liebert Young Investigator Award, AAPS Emerging Leader Award 2021 : NIH MIRA R35 grant ($1.9M), METAvivor Early Career Award 2019 : KL2 Scholar (NCATS, NIH) The Zhu Research Group includes 15+ members working on projects like tumor therapeutic mRNA vaccines and RNA editing. They currently accept PhD students, postdocs, and visiting scholars.

Sonja SchelhaasView profile

Researcher

• Molecular Imaging
• Optical Imaging
• Molecular Biology
• +2 more

Sonja Schelhaas is a researcher affiliated with the European Institute for Molecular Imaging (EIMI) at the University of Münster. Her work focuses on molecular imaging technologies, particularly in oncology and neurological contexts. PhD in Medical Biochemistry (2007-2010) Postdoc at EIMI since 2010 Research Fellow in Anaesthesiology (2005-2006) Her research spans: PET tracer development for ion channels Molecular imaging of tumor microenvironments Applications of small animal PET in disease models Bacterial and inflammatory imaging Radiochemistry and multimodal imaging techniques Epigenetic regulation in cancer Recent publications highlight her contributions to: P2X4 receptor antagonists for PET tracers KCa31 channel imaging in cancer Bacterial detection via radiolabeled compounds FLT PET for tumor proliferation analysis Neurogenesis and blood-brain barrier studies PEGylated nanoparticle characterization Schelhaas has collaborated extensively in preclinical imaging projects, contributing to cancer research, infection monitoring, and neurodegenerative disease modeling. Her work appears in journals like Journal of Medical Chemistry , Cancer Research , and Molecular Imaging and Biology .

Zoran GajicView profile

Professor

• Control Systems
• Energy Systems
• Wireless Communications
• +4 more

Zoran Gajic is a Professor of Electrical and Computer Engineering at Rutgers University, where he has taught since 1984. He holds academic leadership roles including Graduate Program Director for the Electrical and Computer Engineering Department and President of the Rutgers AAUP-AFT Faculty Union. His expertise spans controls systems, energy systems (including solar, wind, and smart grids), wireless communications, and networking. Education: B.S. and M.S. in Electrical Engineering from University of Belgrade, followed by M.S. in Applied Mathematics and Ph.D. in Systems Science Engineering from Michigan State University (1984). Research focuses on control theory applications for energy systems and communication networks. He has authored/coauthored nearly 100 journal papers and eight books, including best-selling titles like Linear Dynamic Systems and Signals (translated into Chinese) and Lyapunov Matrix Equation in Systems Stability and Control (republished by Dover). His work includes innovations in multirate control systems, singular perturbation methods, and reinforcement learning applications. Professional recognitions include editorial roles across nine journals, five guest-edited special issues, and plenary lectures at international conferences. Ten of his 17 Ph.D. advisees hold faculty positions globally. Beyond academia, he is a chess master with Life Master ranking from the U.S. Chess Federation and World Chess Federation certification. Key contributions include foundational work on optimal control for renewable energy systems, sliding mode control algorithms, and system decomposition techniques. His research has been supported by NSF and industry partners like AT&T Bell Labs. He leads the Rutgers Center for Systems and Controls (SYCON) as Associate Director and actively contributes to standards through IEEE and IEC initiatives, particularly in power system protection and control system reliability.

Edwin HwuView profile

Associate Professor

• Atomic Force Microscopy
• 3D Printing
• Drug Delivery
• +3 more

Edwin Hwu is an Associate Professor at the Department of Health Technology, Technical University of Denmark (DTU), leading the MIDAS research group focused on Micro Medical Devices and hardware hacking-based technologies. His work spans Atomic Force Microscopy (AFM), 3D printing, and drug delivery systems. Research Focus: Skin barrier function assessment, liver fibrosis treatment using siRNA, and repurposing consumer electronics for biomedical sensing. Projects: Currently leads "Repurposing Microelectronics for Gut Sensing" (2025-2028) and previously completed "Rapid Clinical Assessment of Skin Barrier Function by Corneocytes Nanotexture" (2021-2023). His publications highlight interdisciplinary work in Atomic Force Microscopy , 3D Printing , and Nanoscale Engineering , with applications in dermatology and neglected tropical diseases. He actively engages in guest lectures on hacking consumer electronics for scientific research. Awards: VILLUM Experiment Grant for micro/nanoscale 3D printing projects. Hwu supervises PhD students and collaborates with researchers like Anja Boisen (DTU) and others, focusing on translating microelectronics into medical solutions. His lab develops compact, high-resolution devices for diagnostics and drug delivery.

Paula HammondView profile

Professor

• Nanotechnology
• Chemical Engineering
• Drug Delivery
• +12 more

Paula T. Hammond is the David H. Koch Professor of Engineering, head of the Department of Chemical Engineering, and a member of the Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology. A pioneer in nanotechnology and polymer science, she develops layer-by-layer (LbL) nanoparticle platforms for cancer therapy, wound healing, vaccine delivery, and synthetic blood substitutes. Her work bridges chemical engineering, materials science, and biomedical applications with a focus on translational research. BS in Chemical Engineering, MIT (1984) MS in Chemical Engineering, Georgia Tech (1988) PhD in Chemical Engineering, MIT (1993) Research Interests : Hammond’s research spans nano-based drug delivery , immunotherapy , biomedical implants , and self-assembling materials . Her lab designs LbL nanoparticles for ovarian cancer , glioblastoma , and intractable cancers , enabling combination therapies (siRNA, proteins, chemotherapy). Recent work includes ML-driven nanoparticle design and two-component hemostatic systems for internal bleeding. Article Trends : Her recent publications (2025) emphasize modular LbL nanoparticles for hematopoietic stem cells , cancer immunostimulation , and multi-drug delivery . Broader keywords include Nanotechnology , Biomaterials , RNA Therapeutics , while sub-fields cover targeted drug release , immune activation , and synthetic oxygen transport . Scientific Awards : National Medal of Technology and Innovation (2024) Othmer Gold Medal (2024) Benjamin Franklin Medal in Chemistry (2024) James R. Killian Faculty Achievement Award (2023-24) MIT Institute Professor (2021) Three-time National Academy member (Sciences, Engineering, Medicine) Advising & Leadership : Hammond has mentored over 60 graduate students and postdocs , co-founded LayerBio, Inc. , and serves on scientific advisory boards for Moderna and Burroughs-Wellcome Fund . She chairs MIT’s Initiative on Faculty Race and Diversity and contributes to national science policy through PCAST. Lab & Collaborations : The Hammond Lab at MIT’s Koch Institute develops LbL nanoparticle systems with applications in cancer, regenerative medicine, and hemostasis. Collaborations include the MIT Institute for Soldier Nanotechnology and partnerships with clinicians, biologists, and engineers.

Anna BarnardView profile

Associate Professor

• Medicinal and Biomolecular Chemistry
• Organic Chemistry
• Biochemistry and Cell Biology
• +8 more

Dr. Anna Barnard is an Associate Professor (Senior Lecturer) in the Department of Chemistry at Imperial College London, affiliated with the Institute of Chemical Biology and multiple research groups including the Barnard Group. Her research focuses on developing chemical tools to target protein-protein interactions (PPIs), with applications in infectious diseases, cancer, and antibiotic resistance. She holds a Wellcome Trust Sir Henry Dale Fellowship (2019-2025) and leads a multidisciplinary team in drug discovery, peptide engineering, and chemical biology. Education: PhD in Chemistry (University of York, 2012), postdoctoral training at the University of Leeds, Imperial College London, and a Junior Research Fellowship at Imperial (2015). She has authored over 30 publications in journals like Chemical Science , Journal of the American Chemical Society , and ACS Chemical Biology . Research Interests: Design of helix mimetics, stapled peptides, and small molecule inhibitors; targeting bacterial toxins (e.g., Doc in Salmonella); malaria transmission-blocking agents; and applications of molecular rotors for live-cell imaging of PPI inhibition. Her work bridges organic chemistry, synthetic biology, and translational medicine. Awards: Wellcome Trust Sir Henry Dale Fellowship, Imperial College Network of Excellence in Malaria. Collaborations include Imperial’s Department of Medicine, the Institute of Infection, and industry partners like FreshCheck. She mentors over 20 current and past students, including PhD candidates and MRes researchers. Labs/Teams: Barnard Group (Chemical Biology), Institute of Chemical Biology (CDT in Chemical Biology), and cross-disciplinary initiatives with the Kuimova, Fuchter, and Tate groups. Research is funded by Wellcome Trust, EPSRC, and Imperial College scholarships.

• Molecular Virology
• RNA Biology
• Plant Biotechnology
• +5 more

Prof. Dr. Sven-Erik Behrens serves as a Professor in the Department of Microbial Biotechnology at the Faculty of Natural Sciences I of Martin Luther University Halle-Wittenberg. He is affiliated with the Protein Research Center 'Charles Tanford' and maintains an active research program focused on RNA biology, molecular virology, and biotechnological applications. His primary research interests encompass RNA-based plant protection strategies, viral replication mechanisms (particularly for flaviviruses and plant viruses), and innovative vaccine development using Kluyveromyces lactis yeast expression systems. Behrens' work investigates fundamental RNA-protein interactions, RNA chaperone activities, and the molecular basis of antiviral defense mechanisms in plants. His laboratory explores how RNA accessibility influences viral replication and how this knowledge can be harnessed for developing novel RNA-based antiviral strategies. Analysis of his recent publications (2021-2025) reveals a clear research trajectory focused on identifying accessible RNA sites for targeted antiviral applications, optimizing yeast-based vaccine platforms for both plant and animal pathogens, and investigating the role of non-coding RNAs in plant development and stress responses. His work spans multiple disciplines including plant virology, medical virology, and microbial biotechnology, demonstrating translational research from basic molecular mechanisms to practical applications. Prof. Behrens leads research in the Department of Microbial Biotechnology, collaborating with various groups working on plant-pathogen interactions and vaccine development. His laboratory employs advanced techniques including RNA structure probing, fluorescence-based assays for RNA chaperone activity, and plant in vitro systems for studying viral replication. The research demonstrates significant potential for developing novel approaches to combat viral diseases in both agricultural and medical contexts.

• Non-viral Gene Therapy
• Orthopedic Surgery
• Bone Quality Analysis
• +5 more

Julio Fernandes is a Full Professor in the Department of Surgery at the University of Montreal’s Faculty of Medicine and holds the University of Montreal Research Chair in Orthopedics at the Hôpital du Sacré-Cœur de Montréal. He is a globally recognized leader in orthopedic surgery and non-viral gene therapy using polymeric nanoparticles. His research focuses on osteoporosis, bone quality analysis, surgical instrumentation, and advanced therapies for arthritis and fractures. Education: MD, MSc Affiliations: CIUSSS Nord-de-l’Île-de-Montréal, Hôpital du Sacré-Cœur de Montréal International Collaborations: Brazil, China, USA, Europe Research Highlights: Over CAD 13 million in funding since 2000, 68 international invited lectures, and pioneering work on chitosan-based nanoparticles for gene delivery. Key projects include developing resolvin analogues for osteoporosis therapy and investigating 4-hydroxynonenal’s role in osteoarthritis. Advising & Grants: Supervised 16+ graduate students (PhD/MSc), led projects like the CAD 1.3M ‘Science Without Borders’ program. Major grants include IRSC and FQRNT funding for bone metabolism and nanomedicine research. Labs & Teams: Leads the Orthopedic Research Chair and collaborates with global teams on biomaterials, fracture prevention, and gene therapy.